RT Journal Article
SR Electronic
T1 Three More Drugs Judged “Breakthroughs”
JF Cancer Discovery
JO CANCER DISCOVERY
FD American Association for Cancer Research
SP OF2
OP OF2
DO 10.1158/2159-8290.CD-NB2013-142
VO 3
IS 11
YR 2013
UL http://cancerdiscovery.aacrjournals.org/content/3/11/OF2.abstract
AB The U.S. Food and Drug Administration has granted Breakthrough Therapy status to volasertib, entinostat, and alectinib, which are under development for the treatment of acute myeloid leukemia, estrogen receptor–positive breast cancer, and non–small cell lung cancer, respectively.